As many as 30% of compounds never reach the market because of liver metabolism and toxicity issues. Additionally, liver toxicity is a main reason drugs are recalled from pharmacy shelves post product introduction. Why such a high attrition rate?
Licensed from MIT, the HepatoPac platform addresses these issues by providing a highly functional and stable culture that mimics the human liver.
Organizational Drug-Development Pipeline
If not discovered, hepatotoxic compounds advance through clinical trials, resulting in misappropriated time and money. HepatoPac improves the likelihood of identifying hepatotoxicity by 30% during the pre-clinical phase - a cost-effective solution that focuses your company's efforts on improved drug candidates and ultimately saves millions of dollars.
|Application Note||HepatoPac® A Bioengineered Micro-Liver Platform for Predictive Drug Metabolism and Toxicity Studies. A Predictive, In Vitro Micro-Liver Co-culture System Providing In Vivo Performance|
|Case Study||Ability of a Micropatterned Hepatocyte Co-culture System to Generate Major Human Drug Metabolites.|
|Publication||Bridging in vitro and in vivo metabolism and transport of faldaprevir in humans using a novel cocultured human hepatocyte system, HepatoPac®. Drug Metab and Dispos . Early Access. December 2013.|
|Publication||Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac® Drug Metab and Dispos. Vol. 41(12), p 2024-2032 (2013).|
|Publication||Bioactivation and Toxicity of Acetaminophen in a Rat Hepatocyte Micropatterned Coculture System. Journal of Biochemical and Molecular Toxicology. Early Release Epub, August 5, 2013.|
|Publication||The Use of Micropatterned Co-Cultures to Detect Compounds that Cause Drug induced Liver Injury in Humans. Toxicol. Sci. 132 (1): p 107-117, (2013).|
|Publication||Microscale culture of human liver cells for drug development. Nat Biotechnol, 26(1), 120-126 (2007).|